Does TACROLIMUS Cause Product use in unapproved indication? 5,057 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 5,057 reports of Product use in unapproved indication have been filed in association with TACROLIMUS (Tacrolimus). This represents 5.6% of all adverse event reports for TACROLIMUS.
5,057
Reports of Product use in unapproved indication with TACROLIMUS
5.6%
of all TACROLIMUS reports
744
Deaths
1,272
Hospitalizations
How Dangerous Is Product use in unapproved indication From TACROLIMUS?
Of the 5,057 reports, 744 (14.7%) resulted in death, 1,272 (25.2%) required hospitalization, and 258 (5.1%) were considered life-threatening.
Is Product use in unapproved indication Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TACROLIMUS. However, 5,057 reports have been filed with the FAERS database.
What Other Side Effects Does TACROLIMUS Cause?
Off label use (8,718)
Drug ineffective (6,214)
Acute kidney injury (4,005)
Transplant rejection (3,526)
Cytomegalovirus infection (3,320)
Covid-19 (3,201)
Drug interaction (2,896)
Diarrhoea (2,854)
Toxicity to various agents (2,845)
Death (2,762)
What Other Drugs Cause Product use in unapproved indication?
DUPILUMAB (33,452)
DICLOFENAC (12,197)
METHOTREXATE (8,930)
PREDNISONE (7,625)
RITUXIMAB (7,519)
MYCOPHENOLATE MOFETIL (5,910)
ACETAMINOPHEN (5,819)
CYCLOPHOSPHAMIDE (5,750)
RISPERIDONE (5,551)
CYCLOSPORINE (5,019)
Which TACROLIMUS Alternatives Have Lower Product use in unapproved indication Risk?
TACROLIMUS vs TACROLIMUS\TACROLIMUS ANHYDROUS
TACROLIMUS vs TADALAFIL
TACROLIMUS vs TAFAMIDIS
TACROLIMUS vs TAFAMIDIS MEGLUMINE
TACROLIMUS vs TAFASITAMAB